Compare Macy's Inc (M) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Macy's Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Macy's Inc trades at $22.88 (market cap $5.95B), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $128.16B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 21.5× Macy's Inc's market cap, and Macy's Inc pays a 3.36% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Macy's Inc for 58 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| M | VRTX | |
|---|---|---|
Market Cap | $5.95B | $128.16B |
Volume | 11,329,747 | 806,603 |
Sector | Consumer Cyclical | Health |
52-Week High | $26.21 | $557.96 |
52-Week Low | $16.51 | $407.37 |
Typical Hold Time | 58 Days | 120 Days |
Enterprise Value | $9.75B | $122.29B |
Dividend Yield | 3.36% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Macy's stock trades at $22.79, up 1.47% with a bullish technical signal and strong valuation metrics including a P/E of 8.35 and P/S of 0.27. The company has beaten earnings estimates for three consecutive quarters and maintains a 3.5% dividend yield. Recent 'Bold New Chapter' strategy initiatives are showing traction with improved sales and operational metrics.
The stock offers attractive value with upside to the $24.25 consensus target, though Q3 earnings risk and retail sector headwinds remain concerns. Positive cash flow generation and debt reduction support the dividend, while digital transformation efforts provide growth catalysts.
Vertex Pharmaceuticals (VRTX) trades at $503.25, showing modest daily gains of 0.16%. The stock faces bearish technical signals with mixed earnings performance, missing Q4 2025 and Q2 2026 EPS estimates but beating Q1 2026. Strong fundamentals include 86% gross margins and 35% net income margins, with revenue projected to grow from $12B to $12.6B in 2026. Recent positive Phase II data for kidney disease drug inaxaplin highlights pipeline progress.
Outlook remains positive with 84% analyst buy ratings and $573 consensus target offering 14% upside. Key risks include reliance on cystic fibrosis franchise and competitive pressures. Earnings consistency and pipeline execution are critical for sustained growth amid current technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Macy's Inc
Founded in 1858 and based in New York City, Macy's operates 570 stores under the Macy's nameplate, 58 stores under the Bloomingdale's nameplate, and 160 freestanding Bluemercury specialty beauty stores (as of the end of fiscal-year 2021). Macy's also operates e-commerce sites and licenses two Bloomingdale's stores in the United Arab Emirates and Kuwait. Women's apparel, accessories, shoes, cosmetics, and fragrances comprised 59% of Macy's 2021 sales.
Read more on M →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
